Healthcare Analytics · Published 2025-09-17 · DOI 10.1016/j.health.2025.100419
Current clinical methods for chronic pain assessment lack objective, quantitative measures, creating a critical gap in diagnostic accuracy. This review investigates the relationship between chronic pain and key biomarkers detectable in body fluids, such as glutamate, interleukin-6, nitric oxide, and quinolinic acid. We first discuss the biological mechanisms underlying chronic pain and evaluate the relevance of these biomarkers. The review then focuses on recent advancements in non-enzymatic electrochemical biosensors used to monitor these biomarkers. For each sensor, we summarize performance metrics including sensitivity, detection limits, and linear range, while highlighting the analytical methodologies used to establish correlations between biomarker levels and pain intensity. Our findings demonstrate that quantitative analysis of biomarker fluctuations can enhance chronic pain monitoring. The integration of sensor-based biomarker analytics with clinical workflows may offer a path toward personalized treatment plans and improved decision-making in healthcare supply chains. This review emphasizes the need for continued development of high-precision biosensors as analytical tools for translating physiological signals into clinically actionable pain metrics.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →